Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keisuke Shirai

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Neoplasia (New York, N.Y.)|September 24, 2016
Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver GenesLaura J Tafe, Kirsten J Pierce, Jason D Peterson, et al.
NPJ Precision Oncology|November 18, 2024
Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapyZe Zhang, Kartik Sehgal, Keisuke Shirai, et al.
World Journal of Oncology|January 21, 2022
Advances in Oncology in US and Japan: Focusing on Cancer and Infectious DiseasesHiroto Nakano, Takuto Miyamoto, Yelena Y Janjigian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2011
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring responseSahar A Saddoughi, Elizabeth Garrett-Mayer, Uzair Chaudhary, et al.
Journal for Immunotherapy of Cancer|May 11, 2022
Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinomaGino Kim In, Aparna Nallagangula, Jacob Seung Choi, et al.
The American Journal of Surgical Pathology|May 18, 2021
Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic PitfallDarcy A Kerr, Lester D R Thompson, Laura J Tafe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2018
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity TrialTerry A Day, Keisuke Shirai, Paul E O'Brien, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
JAMA Oncology|June 23, 2018
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical TrialRobert L Ferris, Nabil F Saba, Barbara J Gitlitz, et al.
Journal for Immunotherapy of Cancer|October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Neoplasia (New York, N.Y.)|September 24, 2016
Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver GenesLaura J Tafe, Kirsten J Pierce, Jason D Peterson, et al.
NPJ Precision Oncology|November 18, 2024
Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapyZe Zhang, Kartik Sehgal, Keisuke Shirai, et al.
World Journal of Oncology|January 21, 2022
Advances in Oncology in US and Japan: Focusing on Cancer and Infectious DiseasesHiroto Nakano, Takuto Miyamoto, Yelena Y Janjigian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2011
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring responseSahar A Saddoughi, Elizabeth Garrett-Mayer, Uzair Chaudhary, et al.
Journal for Immunotherapy of Cancer|May 11, 2022
Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinomaGino Kim In, Aparna Nallagangula, Jacob Seung Choi, et al.
The American Journal of Surgical Pathology|May 18, 2021
Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic PitfallDarcy A Kerr, Lester D R Thompson, Laura J Tafe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2018
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity TrialTerry A Day, Keisuke Shirai, Paul E O'Brien, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
JAMA Oncology|June 23, 2018
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical TrialRobert L Ferris, Nabil F Saba, Barbara J Gitlitz, et al.
Journal for Immunotherapy of Cancer|October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.
Pageof 9